Business Wire

Medical Technology Leaders to Discuss Open Data During World Patient Safety, Science & Technology Summit

Del

The medical technology field spans a multi-billion dollar market, and corporate competitiveness has long been viewed as the key to staying ahead. But Joe Kiani, Chairman, and CEO of the medical technology company, Masimo, is bringing fierce competitors together for the sake of patient safety.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005514/en/

Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation, discusses the importance  ...

Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation, discusses the importance of open data and interoperability of medical devices. (Photo: Business Wire)

As a strong advocate for patient safety, Kiani founded the Patient Safety Movement Foundation to stem the needless deaths that occur in hospitals every day through preventable medical error. The goal is zero preventable deaths by 2020.

One of the ways to reach such an aggressive goal, says Kiani, is a concept called “interoperability” and he wants to use open data to create a “Patient Data Super Highway” to get to there.

“First of all, it’s the right thing to do,” Kiani says. “People are dying because of the lack of data sharing –algorithms that can warn clinicians and help them with decision making can’t be used because data from medical devices and electronic medical records have historically been walled by the manufacturers.”

Since the first Patient Safety Science & Technology Summit in January 2013, Kiani has convened hundreds of leading clinicians, hospital CEOs, medical technology CEOs, government stakeholders and patient advocates from around the globe to discuss what steps need to be made to get closer to the Foundation’s goal to eliminate preventable deaths in hospitals.

The first challenge is how to get competing MedTech companies like Philips, Medtronic, Masimo and GE to work together on interoperability? The solution is through Open Data Pledges to amass data collected by various medical devices. Data sharing is the key along with protections for patient privacy, but the prize remains patient safety. The information is there, ready for any company or entrepreneur to figure out a way to take “interoperability and with it predictive algorithms and decision support” from concept to reality.

What began with nine companies opting to sign Open Data Pledge in 2013 has now grown to nearly 100 companies, including giants GE, IBM Watson, Medtronic and Philips, who have signed the pledge. And this year, Medtronic CEO Omar Ishrak will lead the panel on Healthcare Technology at the 6th Annual World Patient Safety, Science & Technology Summit in London. It’s a clear sign that more companies are beginning to see the need for interoperability to eliminate preventable deaths in hospitals.

“That’s what makes this year’s World Patient Safety, Science and Technology Summit so exciting,” says Kiani. “We are going to be able to bring together industry leaders, innovators and even rivals to the table in pursuit of patient safety.”

“Zero preventable deaths in a hospital setting by 2020 is a goal worth cooperating for,” Kiani says. “The summit brings together the expertise, technology and the ability to come up with actionable plans and implementation that can save lives.”

The 6th Annual World Patient Healthcare Technology Leadership panelists are:

  • Moderator Omar Ishrak , Chairman and CEO, Medtronic – Past President and CEO of General Electric Healthcare Systems, a 12 billion dollar division of GE. He is co-chair of the World Economic Forum’s Health and Healthcare Community and serves on the Board of Directors for Intel, the global technology company.
  • Matt Darling , Co-founder, SmartWard – Mr. Darling’s diverse background includes bringing hardware and software solutions in Cybersecurity, Safety-Critical Systems, and Defense.
  • Frans van Houten , CEO, Royal Philips – Mr. van Houten also serves as Chairman of the Board of Management and Executive Committees. His expertise in innovation and business transformation has led to improved results at Philips through targeted divestment and the acquisition of complementary health technology businesses. These include U.S. based image-guided therapy leader Volcano and analytics leader Wellcentive.
  • Anders Wold , President and CEO, GE Healthcare Clinical Care Solutions - Mr. Wold joined GE with the acquisition of Diasonics/Vingmed Ultrasound, a Norway-based technology start-up. He has 32- years of experience in the ultrasound industry, including product management, sales and marketing while based in Singapore, Paris and Norway. He led the Global Ultrasound business from 2009 to July 2016, growing it into the global industry leader.
  • Dr. Charles Murphy , Chief Patient Safety Officer, Inova Heart and Vascular Institute - Dr. Murphy continues to be active in direct patient care as a critical care physician and medical director of the Cardiovascular ICU at Inova. He previously served as Associate Chief Patient Safety Officer for the Duke Health System.

For more information, please visit the Patient Safety Movement Foundation website. Members of the media may request a press pass by visiting http://bit.ly/2mCeyay or by contacting Tanya Lyon – phone (949) 351-2858 or email tanya.lyon@patientsafetymovement.org.

About Patient Safety Movement Foundation:

More than 200,000 U.S. patients and three million worldwide die each year from preventable causes. The Patient Safety Movement Foundation (PSMF) was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to zero by 2020 (0X2020). Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The PSMF works with all stakeholders to address problems with actionable solutions. The Foundation also convenes the World Patient Safety, Science and Technology Summit bringing together some of the world’s best minds for thought-provoking discussions and new ideas that challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.

Contact information

Patient Safety Movement Foundation
Tanya Lyon, 949-351-2858
tanya.lyon@patientsafetymovement.org

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 10:49Pressemelding

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha